Ovarian rejuvenation for menopausal or perimenopausal women using autologous platelet rich plasma (A-PRP) injection into the ovaries, for women seeking in vitro fertilisation (IVF) treatment, aiming to improve IVF outcomes.

Not Applicable

Recruiting

• Conditions: Premature ovarian failure; Poor ovarian response; Advanced maternal age; Reproductive Health and Childbirth - Fertility including in vitro fertilisation

• Registration Number: ACTRN12619001206112
• Lead Sponsor: Fertility North

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-08-29
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 400

Inclusion Criteria

i.Low AMH (<1.5 pmol/L).
ii.High basal FSH (>14 mIU/mL).
iii.Classified with premature ovarian failure (POF) (Menopausal reproductive hormones <40 years of age).
iv.Classified as having poor ovarian response (POR) (As per Bologna Criteria).
v.A history of poor IVF outcomes, including failed oocyte retrievals, no mature oocytes available for insemination, failed fertilisation of oocytes, no embryos available for transfer.

Exclusion Criteria

i.Patients with normal hormonal profiles, previous acceptable / good responses to ovarian stimulation and good numbers of embryos available for embryo transfer or cryopreservation (greater than 3).
ii.Patients with POF due to a genetic condition e.g. Turners syndrome.
iii.Patients with Idiopathic thrombocytopenia (autoimmune platelet deficiency).
iv.Patients who are unable to undergo an IVF treatment cycle for any reason.

Study & Design

• Study Type: Interventional
• Study Design: Not specified